Search - tctmd.com

Displaying 221 - 240 of 962

Sort: Relevancy | Date

Guideline-Directed Therapies Underused in Frail HF Patients

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

March 11, 2022

Antithrombotics Not Worth the Risk During Endovascular Stroke Therapy

News Daily News

Antithrombotics Not Worth the Risk During Endovascular Stroke Therapy

March 07, 2022

Chinese Herbal Formula Matches Losartan in Patients With Mild Hypertension

News Daily News

Chinese Herbal Formula Matches Losartan in Patients With Mild Hypertension

February 11, 2022

CHOICE-MI: TMVR Mortality Much Lower With Newer Transseptal Devices

News Conference News STS 2022

CHOICE-MI: TMVR Mortality Much Lower With Newer Transseptal Devices

February 03, 2022

Before and After PCI, Women Have Poorer Health Status Than Men

News Daily News

Before and After PCI, Women Have Poorer Health Status Than Men

January 28, 2022

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

January 26, 2022

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

Realistic Expectations Emerge After Initial Excitement Over Xenotransplant

News Features

Realistic Expectations Emerge After Initial Excitement Over Xenotransplant

Yael L. Maxwell

January 21, 2022

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

The ‘Black Box’ of Asymptomatic, Stable, Ischemic CAD Treated With PCI

News Daily News

The ‘Black Box’ of Asymptomatic, Stable, Ischemic CAD Treated With PCI

December 09, 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

News Conference News PCR London Valves 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Michael O'Riordan

November 26, 2021

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

News Conference News TCT 2021

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

November 06, 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

November 05, 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

News Conference News TCT 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

November 05, 2021

Heart Failure Interventions – Defining Optimal Medical Therapy in a Device Trial, From FDA Perspective

Presentation TCT 2021

Heart Failure Interventions – Defining Optimal Medical Therapy in a Device Trial, From FDA Perspective

Presenter: Meir Shinnar

November 05, 2021

Heart Failure Interventions – Defining Optimal Medical Therapy in a Device Trial, From Academic Perspective

Presentation TCT 2021

Heart Failure Interventions – Defining Optimal Medical Therapy in a Device Trial, From Academic Perspective

Presenter: William Abraham

November 05, 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.